Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

3.200 +0.150 (+4.92%)

Streaming Delayed Price Updated: 3:29 PM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS ↗

June 03, 2021

Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In...

Via Benzinga

Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson

June 02, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021

June 02, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS ↗

May 27, 2021

by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address...

Via Benzinga

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update

May 27, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

May 27, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES ↗

May 12, 2021

Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...

Via Benzinga

Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021

May 06, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

April 29, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Expands Mid-Stage COVID-19 Study To Europe ↗

April 22, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized,...

Via Benzinga

Can-Fite Expands its Phase II COVID-19 Study to Europe

April 22, 2021

From Can-Fite BioPharma Ltd

Via Business Wire

Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing ↗

April 20, 2021

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for...

Via Benzinga

Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates

April 20, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.